{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T02:25:21Z","timestamp":1777861521865,"version":"3.51.4"},"reference-count":174,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Small cell lung cancer (SCLC) remains one of the most aggressive malignancies, characterized by rapid proliferation, early metastatic dissemination, and poor long-term survival despite initial sensitivity to therapy. SCLC shares several biologic and therapeutic principles with hematologic malignancies, including lineage state dependence, adaptive resistance through non-genetic plasticity, and emerging susceptibility to antigen-directed immune therapies. Reframing SCLC through this lens provides a conceptual framework for understanding treatment failure and identifying new therapeutic strategies. A defining feature of SCLC is its dynamic transition between neuroendocrine (NE) and non-neuroendocrine (non-NE) states, driven by epigenetic and transcriptional reprogramming rather than new genetic alterations. These state transitions regulate antigen expression, immune visibility, and therapeutic vulnerability, enabling tumors to evade both cytotoxic and immune-based treatments. This plasticity parallels lineage switching and antigen escape observed in hematologic malignancies treated with targeted and immune therapies. Recent advances in antigen-directed therapy, particularly bispecific T cell engagers and antibody-drug conjugates targeting lineage-associated proteins such as DLL3, SEZ6, and TROP2, have demonstrated promising clinical activity. However, therapeutic efficacy is limited by antigen heterogeneity, evolving tumor states, and microenvironmental barriers including immune exclusion and T cell dysfunction. Epigenetic therapies targeting regulators such as EZH2 and LSD1 offer a strategy to reprogram tumor state, enhance antigen presentation, and sensitize tumors to immunotherapy. Beyond lineage biology, SCLC exhibits dependence on replication stress and DNA damage response pathways, though targeting these vulnerabilities alone has yielded modest clinical benefit. Emerging evidence highlights the role of metabolic and stress-response adaptations, including lactate-mediated immune suppression and integrated stress signaling, in sustaining tumor fitness and resistance. Circulating tumor DNA and epigenomic profiling provide noninvasive approaches to monitor tumor evolution, lineage state, and treatment response over time, offering potential for biomarker-guided therapeutic adaptation. Overall, durable clinical benefit in SCLC will likely require temporally sequenced, biomarker driven combination strategies that anticipate and constrain tumor plasticity. Integrating lineage-directed targeting, epigenetic modulation, immune engagement, and metabolic intervention may enable more effective and sustained disease control in this highly adaptive cancer.<\/jats:p>","DOI":"10.3389\/fonc.2026.1821271","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T04:21:44Z","timestamp":1777522904000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Reframing small cell lung cancer: therapeutic lessons from hematologic malignancies"],"prefix":"10.3389","volume":"16","author":[{"given":"Kanak","family":"Parmar","sequence":"first","affiliation":[{"name":"National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH)","place":["Bethesda, MD, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ira","family":"Surolia","sequence":"additional","affiliation":[{"name":"Hartford Healthcare","place":["Hartford, MD, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anish","family":"Thomas","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Branch, National Cancer Institute (NCI), National Institutes of Health (NIH)","place":["Bethesda, MD, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.0560","article-title":"Small cell lung cancer: a review","volume":"333","author":"Kim","year":"2025","journal-title":"Jama"},{"key":"B2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(24)00428-4","article-title":"Estimated worldwide variation and trends in incidence of lung cancer by histological subtype in 2022 and over time: a population-based study","volume":"13","author":"Luo","year":"2025","journal-title":"Lancet Respir Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abc7488","article-title":"Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair-targeted therapies","volume":"13","author":"Tlemsani","year":"2021","journal-title":"Sci Transl Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-4259","article-title":"Veliparib in combination with carboplatin and etoposide in patients with treatment-na\u00efve extensive-stage small cell lung cancer: a phase 2 randomized study","volume":"27","author":"Byers","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32909","article-title":"The BiTE (bispecific T-cell engager) platform: development and future potential of a targeted immuno-oncology therapy across tumor types","volume":"126","author":"Einsele","year":"2020","journal-title":"Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"S1546","DOI":"10.1016\/j.jtho.2017.06.062","article-title":"Small cell lung cancer and the recalcitrant cancer research act","volume":"12","author":"Lindwasser","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-14-2958","article-title":"Small cell lung cancer: will recent progress lead to improved outcomes","volume":"21","author":"Pietanza","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2020.07.003","article-title":"Bone marrow involvement in small cell lung cancer","volume":"43","author":"Loscocco","year":"2021","journal-title":"Hematol Transfus Cell Ther"},{"key":"B10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ccell.2019.06.005","article-title":"Pan-cancer convergence to a small-cell neuroendocrine phenotype that shares susceptibilities with hematological Malignancies","volume":"36","author":"Balanis","year":"2019","journal-title":"Cancer Cell"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-16-0459","article-title":"Vulnerability of small-cell lung cancer to apoptosis induced by the combination of BET bromodomain proteins and BCL2 inhibitors","volume":"16","author":"Lam","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2021.04.005","article-title":"A phase II trial of prexasertib (LY2606368) in patients with extensive-stage small-cell lung cancer","volume":"22","author":"Byers","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-11-3090","article-title":"Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer","volume":"18","author":"Rudin","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2011.05.005","article-title":"A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer","volume":"74","author":"Paik","year":"2011","journal-title":"Lung Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/1878-0261.12829","article-title":"Identification of RUNX1T1 as a potential epigenetic modifier in small-cell lung cancer","volume":"15","author":"He","year":"2021","journal-title":"Mol Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-05-644872","article-title":"ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells","volume":"127","author":"Kwok","year":"2016","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-20-0913","article-title":"Intrinsic immunogenicity of small cell lung carcinoma revealed by its cellular plasticity","volume":"11","author":"Mahadevan","year":"2021","journal-title":"Cancer Discov"},{"key":"B18","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3324\/haematol.2015.132761","article-title":"The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints","volume":"101","author":"Santosha","year":"2016","journal-title":"Hematologica"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-24-3192","article-title":"Mechanism of initial favorable response to decitabine in TP53-mutated MDS\/AML and potential mechanisms of subsequent relapse","volume":"31","author":"Ng","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1172\/jci78789","article-title":"Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes","volume":"125","author":"Saunthararajah","year":"2015","journal-title":"J Clin Invest"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2022.2099578","article-title":"DNA methyltransferase-1 in acute myeloid leukemia: beyond the maintenance of DNA methylation","volume":"54","author":"Li","year":"2022","journal-title":"Ann Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.01.006","article-title":"Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 axis","volume":"31","author":"Gardner","year":"2017","journal-title":"Cancer Cell"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/jto.0b013e318298762f","article-title":"EZH2 promotes E2F-driven SCLC tumorigenesis through modulation of apoptosis and cell-cycle regulation","volume":"8","author":"Hubaux","year":"2013","journal-title":"J Thorac Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/s41568-019-0219-4","article-title":"PRC2-mediated MHC-I silencing drives immune evasion","volume":"19","author":"Bradley","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-23-3383","article-title":"A phase I\/II study of valemetostat (DS-3201b), an EZH1\/2 inhibitor, in combination with irinotecan in patients with recurrent small-cell lung cancer","volume":"30","author":"Choudhury","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","article-title":"Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities","volume":"39","author":"Gay","year":"2021","journal-title":"Cancer Cell"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/edbk-25-472794","article-title":"Taking a bite out of small cell lung cancer by leveraging precision-directed delta-like ligand-3 therapies","volume":"45","author":"Aijaz","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.09.009","article-title":"SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization","volume":"15","author":"Baine","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-25-2090","article-title":"Seizure-related homolog protein 6 (SEZ6): biology and therapeutic target in neuroendocrine carcinomas","volume":"31","author":"Gezelius","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aau2922","article-title":"Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition","volume":"12","author":"Augert","year":"2019","journal-title":"Sci Signal"},{"key":"B32","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13045-024-01572-3","article-title":"SMARCA4 controls state plasticity in small cell lung cancer through regulation of neuroendocrine transcription factors and REST splicing","volume":"17","author":"Redin","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1038\/s41467-022-29517-9","article-title":"Heterogeneity of neuroendocrine transcriptional states in metastatic small cell lung cancers and patient-derived models","volume":"13","author":"Lissa","year":"2022","journal-title":"Nat Commun"},{"key":"B34","doi-asserted-by":"publisher","first-page":"3880","DOI":"10.1038\/s41467-021-24164-y","article-title":"Notch signaling and efficacy of PD-1\/PD-L1 blockade in relapsed small cell lung cancer","volume":"12","author":"Roper","year":"2021","journal-title":"Nat Commun"},{"key":"B35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jtho.2022.10.002","article-title":"SCLC: epidemiology, risk factors, genetic susceptibility, molecular pathology, screening, and early detection","volume":"18","author":"Wang","year":"2023","journal-title":"J Thorac Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abg1850","article-title":"YAP drives fate conversion and chemoresistance of small cell lung cancer","volume":"7","author":"Wu","year":"2021","journal-title":"Sci Adv"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-019-0020-z","article-title":"Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer","volume":"1","author":"Stewart","year":"2020","journal-title":"Nat Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/s42003-021-01842-7","article-title":"Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer","volume":"4","author":"Cai","year":"2021","journal-title":"Commun Biol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2023.109824","article-title":"Activation of the TGF-\u03b21\/EMT signaling pathway by claudin-1 overexpression reduces doxorubicin sensitivity in small cell lung cancer SBC-3 cells","volume":"751","author":"Nagaoka","year":"2024","journal-title":"Arch Biochem Biophys"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00784-7","article-title":"Assessment of targets of antibody drug conjugates in SCLC","volume":"9","author":"Ajay","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.09.149","article-title":"MA07.02 development and prospective validation of a chromatin-based classification for small-cell lung cancer","volume":"20","author":"Kumar","year":"2025","journal-title":"J Thorac Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-18-4140","article-title":"MYC-driven small-cell lung cancer is metabolically distinct and vulnerable to arginine depletion","volume":"25","author":"Chalishazar","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2022.11.006","article-title":"The role of stem cells in small-cell lung cancer: evidence from chemoresistance to immunotherapy","volume":"87","author":"Guo","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"302ra136","DOI":"10.1126\/scitranslmed.aac9459","article-title":"A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo","volume":"7","author":"Saunders","year":"2015","journal-title":"Sci Transl Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.07.012","article-title":"All that glitters is not gold: the story of rovalpituzumab tesirine in SCLC","volume":"16","author":"Uprety","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-19-1133","article-title":"Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing, relapsed\/refractory small-cell lung cancer: results from the phase II TRINITY study","volume":"25","author":"Morgensztern","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.02.009","article-title":"Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second-line therapy in DLL3-high SCLC: results from the phase 3 TAHOE study","volume":"16","author":"Blackhall","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.03.012","article-title":"Rovalpituzumab tesirine as a maintenance therapy after first-line platinum-based chemotherapy in patients with extensive-stage-SCLC: results from the phase 3 MERU study","volume":"16","author":"Johnson","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B49","unstructured":""},{"key":"B50","doi-asserted-by":"publisher","first-page":"3041\u2013","DOI":"10.1200\/jco.2025.43.16_suppl.3041","article-title":"ZL-1310, a DLL3 ADC, in patients with extensive stage small cell lung cancer: Ph1 trial update","volume":"43","author":"Patel","year":"2025","journal-title":"J Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2025.43.17_suppl.lba8008","article-title":"Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): Primary analysis of Ph3 DeLLphi-304","volume":"43","author":"Rudin","year":"2025","journal-title":"J Clin Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N Engl J Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cllc.2025.03.006","article-title":"Real-world outcomes of tarlatamab in small cell lung cancer, including patients with untreated brain metastases","volume":"26","author":"Bolte","year":"2025","journal-title":"Clin Lung Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006680","article-title":"Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody","volume":"11","author":"Park","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B56","unstructured":""},{"key":"B57","doi-asserted-by":"publisher","first-page":"Abstract 2774P","DOI":"10.1016\/j.annonc.2025.08.3385","article-title":"DAREON\u00ae-9: A phase Ib open-label dose escalation and dose confirmation study of obrixtamig (BI 764532) plus topotecan in patients with advanced small-cell lung cancer: updated results","volume":"36","author":"Wermke","year":"2025","journal-title":"Ann Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35738","article-title":"Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3\u2013targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer","volume":"131","author":"Sands","year":"2025","journal-title":"Cancer"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104538","article-title":"Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy","volume":"10","author":"Chiang","year":"2025","journal-title":"ESMO Open"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-2293","article-title":"Allogeneic CAR T cells targeting DLL3 are efficacious and safe in preclinical models of small cell lung cancer","volume":"29","author":"Zhang","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.09.015","article-title":"CAR T cell therapy for solid tumors: Bright future or dark reality","volume":"28","author":"Wagner","year":"2020","journal-title":"Mol Ther"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1172\/jci166028","article-title":"IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models","volume":"133","author":"Jaspers","year":"2023","journal-title":"J Clin Invest"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-1533","article-title":"Radioimmunotherapy targeting delta-like ligand 3 in small cell lung cancer exhibits antitumor efficacy with low toxicity","volume":"28","author":"Tully","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-21-0851","article-title":"ABBV-011, a novel, calicheamicin-based antibody-drug conjugate, targets SEZ6 to eradicate small cell lung cancer tumors","volume":"21","author":"Wiedemeyer","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-24-1547","article-title":"A phase I first-in-human study of ABBV-011, a seizure-related homolog protein 6-targeting antibody-drug conjugate, in patients with small cell lung cancer","volume":"30","author":"Morgensztern","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B66","doi-asserted-by":"publisher","first-page":"3001\u2013","DOI":"10.1200\/jco.2024.42.16_suppl.3001","article-title":"First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)\u2013targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors","volume":"42","author":"Chandana","year":"2024","journal-title":"J Clin Oncol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"8515\u2013","DOI":"10.1200\/jco.2022.40.16_suppl.8515","article-title":"Surfaceome profiling to reveal unique therapeutic vulnerabilities in transcriptional subtypes of small cell lung cancer (SCLC)","volume":"40","author":"Owonikoko","year":"2022","journal-title":"J Clin Oncol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.951589","article-title":"Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132","volume":"12","author":"Cheng","year":"2022","journal-title":"Front Oncol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-025-01705-2","article-title":"Results of a phase 1\/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies","volume":"18","author":"Ouyang","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"101801","DOI":"10.1016\/j.tranon.2023.101801","article-title":"B7-H3\/CD276 and small-cell lung cancer: What\u2019s new","volume":"39","author":"Fabrizio","year":"2024","journal-title":"Transl Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-24-3981","article-title":"Multidimensional analysis of B7 homolog 3 RNA expression in small cell lung cancer molecular subtypes","volume":"31","author":"Gay","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B72","doi-asserted-by":"publisher","first-page":"4891\u2013","DOI":"10.1158\/1538-7445.am2023-4891","article-title":"Abstract 4891: Ifinatamab deruxtecan (I-DXd), a novel B7-H3-targeting antibody-drug conjugate, demonstrates efficient payload delivery into tumor through target-dependent internalization","volume":"83","author":"Katsumata","year":"2023","journal-title":"Cancer Res"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-02142","article-title":"Ifinatamab deruxtecan in patients with extensive-stage small cell lung cancer: Primary analysis of the phase II IDeate-Lung01 trial","volume":"44","author":"Rudin","year":"2026","journal-title":"J Clin Oncol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"S1074","DOI":"10.1016\/j.annonc.2024.08.1903","article-title":"1812TiP IDeate-Lung03: A phase Ib\/II study of ifinatamab deruxtecan (I-DXd) plus atezolizumab (atezo) with or without carboplatin (carbo) as first-line (1L) induction or maintenance in patients (pts) with extensive stage (ES) small cell lung cancer (SCLC)","volume":"35","author":"Rudin","year":"2024","journal-title":"Ann Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007174","article-title":"Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma","volume":"11","author":"Brignole","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B76","article-title":"Biosynthesis and expression of the disialoganglioside GD2, a relevant target antigen on small cell lung carcinoma for monoclonal antibody-mediated cytolysis","volume":"46","author":"Cheresh","year":"1986","journal-title":"Cancer Res"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003897","article-title":"Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer","volume":"10","author":"Reppel","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.crc-23-0259","article-title":"Rejuvenated iPSC-derived GD2-directed CART cells harbor robust cytotoxicity against small cell lung cancer","volume":"4","author":"Kinoshita","year":"2024","journal-title":"Cancer Res Commun"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2022.03.003","article-title":"Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer","volume":"166","author":"Edelman","year":"2022","journal-title":"Lung Cancer"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-23-3157","article-title":"Preclinical development of CAR T cells with antigen-inducible IL18 enforcement to treat GD2-positive solid cancers","volume":"30","author":"Fischer-Riepe","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B81","doi-asserted-by":"publisher","first-page":"100408","DOI":"10.1016\/j.esmoop.2022.100408","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN","volume":"7","author":"Paz-Ares","year":"2022","journal-title":"ESMO Open"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.01363","article-title":"SKYSCRAPER-02: Tiragolumab in combination with atezolizumab plus chemotherapy in untreated extensive-stage small-cell lung cancer","volume":"42","author":"Rudin","year":"2024","journal-title":"J Clin Oncol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-sitc2024.1463","article-title":"1463 Coformulated vibostolimab\/pembrolizumab plus chemotherapy as first-line therapy vs atezolizumab plus chemotherapy for extensive-stage small-cell lung cancer (ES-SCLC): randomized, phase 3 KEYVIBE-008","volume":"12","author":"Sands","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202502183r","article-title":"Expression and clinical implications of LAG-3 in small cell lung cancer","volume":"39","author":"Sun","year":"2025","journal-title":"FASEB J"},{"key":"B85","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/s41392-022-01150-4","article-title":"Single-cell transcriptomic profiling reveals the tumor heterogeneity of small-cell lung cancer","volume":"7","author":"Tian","year":"2022","journal-title":"Signal Transduction Targeted Ther"},{"key":"B86","doi-asserted-by":"publisher","first-page":"6655","DOI":"10.1038\/s41467-021-26821-8","article-title":"Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer","volume":"12","author":"Chen","year":"2021","journal-title":"Nat Commun"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102606","article-title":"Shaping the tumor immune microenvironment of SCLC: Mechanisms, and opportunities for immunotherapy","volume":"120","author":"Chen","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-15-0037","article-title":"Sensitivity of small cell lung cancer to BET inhibition is mediated by regulation of ASCL1 gene expression","volume":"14","author":"Lenhart","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1158\/1538-7445.am2025-1679","article-title":"Abstract 1679: APG-2449, a novel focal adhesion kinase (FAK) inhibitor, enhances the antitumor activity of chemotherapy in preclinical models of small-cell lung cancer (SCLC) with activated FAK","volume":"85","author":"Yu","year":"2025","journal-title":"Cancer Res"},{"key":"B90","doi-asserted-by":"publisher","first-page":"pkz093","DOI":"10.1093\/jncics\/pkz093","article-title":"Phase 1 study of molibresib (GSK525762), a bromodomain and extra-terminal domain protein inhibitor, in NUT carcinoma and other solid tumors","volume":"4","author":"Piha-Paul","year":"2020","journal-title":"JNCI Cancer Spectr"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12671","article-title":"MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells","volume":"7","author":"Kato","year":"2016","journal-title":"Oncotarget"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.22419287.v1","article-title":"NK cells mediate synergistic antitumor effects of combined inhibition of HDAC6 and BET in a SCLC preclinical model","volume":"78","author":"Liu","year":"2018","journal-title":"Cancer Res"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-1128","article-title":"Inhibition of LSD1 with Bomedemstat sensitizes small cell lung cancer to immune checkpoint blockade and T-cell killing","volume":"28","author":"Hiatt","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B94","doi-asserted-by":"publisher","first-page":"S169","DOI":"10.1016\/j.jtho.2023.09.251","article-title":"MA18.10 phase 2 multicohort study of CC-90011, a LSD1 inhibitor, in combination with nivolumab in patients with advanced lung cancer","volume":"18","author":"Rudin","year":"2023","journal-title":"J Thorac Oncol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"114313","DOI":"10.1016\/j.biopha.2023.114313","article-title":"The pharmacological and biological importance of EZH2 signaling in lung cancer","volume":"160","author":"Entezari","year":"2023","journal-title":"Biomedicine Pharmacotherapy"},{"key":"B96","doi-asserted-by":"publisher","first-page":"15026","DOI":"10.1038\/celldisc.2015.26","article-title":"EZH2 promotes progression of small cell lung cancer by suppressing the TGF-\u03b2-Smad-ASCL1 pathway","volume":"1","author":"Murai","year":"2015","journal-title":"Cell Discov"},{"key":"B97","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1101\/2023.02.15.528365","article-title":"Actin dysregulation induces neuroendocrine plasticity and immune evasion: a vulnerability of small cell lung cancer","volume":"17","author":"Seo","year":"2025","journal-title":"Nat Commun"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-24-1755","article-title":"Targeting the EZH2-SLFN11 pathway\u2014a lesson in developing molecularly-informed treatments for recurrent small cell lung cancer","volume":"13","author":"Sun","year":"2024","journal-title":"Trans Cancer Res"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.16_suppl.tps8130","article-title":"Tazemetostat in combination with topotecan and pembrolizumab in patients with recurrent small cell lung cancer","volume":"42","author":"Desai","year":"2024","journal-title":"J Clin Oncol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1172\/jci126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"key":"B101","doi-asserted-by":"publisher","first-page":"50","DOI":"10.21037\/tlcr.2018.02.03","article-title":"Targeting DNA damage repair in small cell lung cancer and the biomarker landscape","volume":"7","author":"Sen","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2018.12.02","article-title":"Temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer","volume":"7","author":"Lazzari","year":"2018","journal-title":"Trans Lung Cancer Res"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-19-0582","article-title":"Combination olaparib and temozolomide in relapsed small-cell lung cancer","volume":"9","author":"Farago","year":"2019","journal-title":"Cancer Discov"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2025.100874","article-title":"PARP inhibitors as therapy for small cell lung carcinoma: A systematic review and meta-analysis of clinical trials","volume":"42","author":"Pratama","year":"2024","journal-title":"Cancer Treat Res Commun"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.04.026","article-title":"Durvalumab in combination with olaparib in patients with relapsed SCLC: results from a phase\u00a0II study","volume":"14","author":"Thomas","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.10.021","article-title":"Phase II randomized study of maintenance atezolizumab versus atezolizumab plus talazoparib in patients with SLFN11 positive extensive-stage SCLC: S1929","volume":"20","author":"Karim","year":"2025","journal-title":"J Thorac Oncol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103348","article-title":"Measurable residual disease in hematologic Malignancies: a biomarker in search of a standard","volume":"86","author":"Chandhok","year":"2025","journal-title":"EClinicalMedicine"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.10.007","article-title":"Profiling of circulating free DNA using targeted and genome-wide sequencing in patients with SCLC","volume":"15","author":"Mohan","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-023-01052-x","article-title":"A meta-analysis of circulating tumor DNA as a survival indicator in small cell lung cancer patients","volume":"23","author":"Li","year":"2023","journal-title":"Clin Exp Med"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2020.100024","article-title":"Blood-based surveillance monitoring of circulating tumor DNA from patients with SCLC detects disease relapse and predicts death in patients with limited-stage disease","volume":"1","author":"Iams","year":"2020","journal-title":"JTO Clin Res Rep"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-25-2011","article-title":"Early ctDNA dynamics inform first-line therapy in patients with extensive-stage small cell lung cancer","volume":"31","author":"Ciardullo","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1200\/po.24.00216","article-title":"Early circulating tumor DNA shedding kinetics for prediction of platinum sensitivity in patients with small cell lung cancer","volume":"8","author":"Murciano-Goroff","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41392-025-02445-y","article-title":"Circulating tumor DNA refines consolidation immunotherapy for limited-stage small cell lung cancer patients","volume":"10","author":"Yang","year":"2025","journal-title":"Signal Transduction Targeted Ther"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-2242","article-title":"Dynamics of sequence and structural cell-free DNA landscapes in small-cell lung cancer","volume":"29","author":"Sivapalan","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B115","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13073-025-01438-4","article-title":"Genomic alterations and transcriptional phenotypes in circulating free DNA and matched metastatic tumor","volume":"17","author":"Takahashi","year":"2025","journal-title":"Genome Med"},{"key":"B116","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ccell.2024.01.001","article-title":"Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes","volume":"42","author":"Heeke","year":"2024","journal-title":"Cancer Cell"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00415-9","article-title":"cfDNA methylome profiling for detection and subtyping of small cell lung cancers","volume":"3","author":"Chemi","year":"2022","journal-title":"Nat Cancer"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.05.806","article-title":"Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set","volume":"32","author":"Klein","year":"2021","journal-title":"Ann Oncol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adk2082","article-title":"Molecular phenotyping of small cell lung cancer using targeted cfDNA profiling of transcriptional regulatory regions","volume":"10","author":"Hiatt","year":"2024","journal-title":"Sci Adv"},{"key":"B120","doi-asserted-by":"publisher","first-page":"5060","DOI":"10.1038\/s41467-021-24994-w","article-title":"Detection and characterization of lung cancer using cell-free DNA fragmentomes","volume":"12","author":"Mathios","year":"2021","journal-title":"Nat Commun"},{"key":"B121","doi-asserted-by":"publisher","first-page":"2022.06.24.497386","DOI":"10.1101\/2022.06.24.497386","article-title":"Subtyping of Small Cell Lung Cancer using plasma cell-free nucleosomes","author":"Fialkoff","year":"2025","journal-title":"bioRxiv"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-025-01369-0","article-title":"Targeting extrachromosomal DNA in human cancers","author":"Wong","year":"2026","journal-title":"Nat Rev Drug Discov"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-024-01949-7","article-title":"Mapping extrachromosomal DNA amplifications during cancer progression","volume":"56","author":"Kim","year":"2024","journal-title":"Nat Genet"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-22-0796","article-title":"Extrachromosomal DNA amplification contributes to small cell lung cancer heterogeneity and is associated with worse outcomes","volume":"13","author":"Pongor","year":"2023","journal-title":"Cancer Discov"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1101\/2023.06.23.546278","article-title":"Acquired cross-resistance in small cell lung cancer due to extrachromosomal DNA amplification of MYC paralogs","volume":"14","author":"Pal Choudhuri","year":"2024","journal-title":"Cancer Discov"},{"key":"B126","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41698-024-00739-y","article-title":"Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms","volume":"8","author":"Serrano","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.2147\/lctt.s511789","article-title":"Tumor heterogeneity and plasticity in small cell lung cancer","volume":"16","author":"Duronio","year":"2025","journal-title":"Lung Cancer: Targets Ther"},{"key":"B128","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1186\/s12967-024-05568-y","article-title":"DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase I inhibitor, exhibits promising safety profile and therapeutic efficacy in preclinical small cell lung cancer models","volume":"22","author":"Lin","year":"2024","journal-title":"J Transl Med"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody\u2013drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-24-0267","article-title":"Potential mechanisms of interstitial lung disease induced by antibody\u2013drug conjugates based on quantitative analysis of drug distribution","volume":"24","author":"Koganemaru","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.2147\/dddt.s508773","article-title":"A systematic review of mechanisms, incidence, and management of trastuzumab deruxtecan induced ILD\/pneumonitis in solid tumors","volume":"19","author":"Liao","year":"2025","journal-title":"Drug Des Devel Ther"},{"key":"B132","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s13014-020-01654-9","article-title":"Radiation-induced lung toxicity \u2013 cellular and molecular mechanisms of pathogenesis, management, and literature review","volume":"15","author":"K\u00e4smann","year":"2020","journal-title":"Radiat Oncol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-nw2025-0107","article-title":"ADC for SCLC clears phase I","volume":"16","year":"2026","journal-title":"Cancer Discov"},{"key":"B134","unstructured":""},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-15-0612","article-title":"FDA approval: blinatumomab","volume":"21","author":"Przepiorka","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2019000018","article-title":"Mechanisms of and approaches to overcoming resistance to immunotherapy","volume":"2019","author":"Schultz","year":"2019","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34667","article-title":"Low leukemia burden improves blinatumomab efficacy in patients with relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"129","author":"Queudeville","year":"2023","journal-title":"Cancer"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2025.2549515","article-title":"Lineage switch of B-lymphoblastic leukemia with KMT2A::AFF1 fusion into acute myelomonocytic leukemia under blinatumomab therapy","volume":"66","author":"Parisi","year":"2025","journal-title":"Leukemia Lymphoma"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025029260","article-title":"Postimmunotherapy lineage switch: where to from here","volume":"146","author":"Kuzich","year":"2025","journal-title":"Blood"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-23-3333","article-title":"T-cell characteristics impact response and resistance to T-cell\u2013redirecting bispecific antibodies in multiple myeloma","volume":"30","author":"Verkleij","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B141","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41408-024-01139-y","article-title":"Bispecific antibodies in the treatment of multiple myeloma","volume":"14","author":"Devasia","year":"2024","journal-title":"Blood Cancer J"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.bcd-25-0062","article-title":"Clinical scores to predict toxicities and outcomes in patients with multiple myeloma undergoing bispecific T-cell engager therapy","author":"Frenking","year":"2026","journal-title":"Blood Cancer Discov"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(24)00186-8","article-title":"Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies","volume":"11","author":"van de Donk","year":"2024","journal-title":"Lancet Hematol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd1524","article-title":"Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell\u2013cold solid tumors","volume":"13","author":"Belmontes","year":"2021","journal-title":"Sci Transl Med"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020287","article-title":"Overcoming challenges for CD3-bispecific antibody therapy in solid tumors","volume":"13","author":"Middelburg","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B146","doi-asserted-by":"publisher","first-page":"2025.12.04.692214","DOI":"10.64898\/2025.12.04.692214","article-title":"T cell engagers control solid tumors through clonal replacement and IL2-driven effector differentiation of CD8 T cells","author":"Obenaus","year":"2026","journal-title":"bioRxiv"},{"key":"B147","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13045-021-01156-5","article-title":"Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response","volume":"14","author":"Park","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-13-3723","article-title":"CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models","volume":"74","author":"Zhu","year":"2014","journal-title":"Cancer Res"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.575737","article-title":"Combination of T-cell bispecific antibodies with PD-L1 checkpoint inhibition elicits superior anti-tumor activity","volume":"10","author":"Sam","year":"2020","journal-title":"Front Oncol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-25-1483","article-title":"Circulating tumor cells predict response to the DLL3-targeting bispecific antibody Tarlatamab","author":"Mishra","year":"2026","journal-title":"Cancer Discov"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717x-9-216","article-title":"Risk factors for brain metastases in completely resected small cell lung cancer: a retrospective study to identify patients most likely to benefit from prophylactic cranial irradiation","volume":"9","author":"Zhu","year":"2014","journal-title":"Radiat Oncol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-20-0291","article-title":"Brain metastasis cell lines panel: a public resource of organotropic cell lines","volume":"80","author":"Valiente","year":"2020","journal-title":"Cancer Res"},{"key":"B153","doi-asserted-by":"publisher","first-page":"2024.10.07.617066","DOI":"10.1101\/2024.10.07.617066","article-title":"Metastatic organotropism in small cell lung cancer","author":"Krishnamurthy","year":"2025","journal-title":"bioRxiv"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-10-1564","article-title":"Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer","volume":"16","author":"Lockman","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.3371","article-title":"2760MO intracranial activity of ifinatamab deruxtecan (I-DXd) in patients (pts) with extensive-stage (ES) small cell lung cancer (SCLC) and baseline (BL) brain metastases (BM): primary analysis of IDeate-Lung01","volume":"36","author":"Simoes da Rocha","year":"2025","journal-title":"Ann Oncol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102396","article-title":"Re-examining prophylactic cranial irradiation in small cell lung cancer: a systematic review and meta-analysis","volume":"67","author":"Gaebe","year":"2024","journal-title":"eClinicalMedicine"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1056\/nejm199908123410703","article-title":"Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission","volume":"341","author":"Aup\u00e9rin","year":"1999","journal-title":"N Engl J Med"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-00221","article-title":"Hippocampal avoidance during prophylactic cranial irradiation for patients with small cell lung cancer: randomized phase II\/III trial NRG-CC003","volume":"43","author":"Gondi","year":"2025","journal-title":"J Clin Oncol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa071780","article-title":"Prophylactic cranial irradiation in extensive small-cell lung cancer","volume":"357","author":"Slotman","year":"2007","journal-title":"N Engl J Med"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up(\u2606)","volume":"32","author":"Dingemans","year":"2021","journal-title":"Ann Oncol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13577-016-0149-3","article-title":"Small cell lung cancer, an epithelial to mesenchymal transition (EMT)-like cancer: significance of inactive Notch signaling and expression of achaete-scute complex homologue 1","volume":"30","author":"Ito","year":"2017","journal-title":"Hum Cell"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101610","article-title":"Microenvironment shapes small-cell lung cancer neuroendocrine states and presents therapeutic opportunities","volume":"5","author":"Desai","year":"2024","journal-title":"Cell Rep Med"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgg.2021.05.007","article-title":"A mesenchymal-like subpopulation in non-neuroendocrine SCLC contributes to metastasis","volume":"48","author":"Jin","year":"2021","journal-title":"J Genet Genomics"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12857","article-title":"TGF\u03b2 promotes YAP-dependent AXL induction in mesenchymal-type lung cancer cells","volume":"15","author":"Choi","year":"2021","journal-title":"Mol Oncol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2023-6206","article-title":"Abstract 6206: Combined inhibition of AXL and ATR enhances replication stress, cell death and immune response in small cell lung cancer","volume":"83","author":"Ramkumar","year":"2023","journal-title":"Cancer Res"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-13-1330","article-title":"Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer","volume":"20","author":"Ca\u00f1adas","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.298","article-title":"MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines","volume":"105","author":"Arriola","year":"2011","journal-title":"Br J Cancer"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102194","article-title":"MET pathway inhibition increases chemo-immunotherapy efficacy in small cell lung cancer","volume":"6","author":"del Rey-Vergara","year":"2025","journal-title":"Cell Rep Med"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.621458","article-title":"Targeting lactate metabolism by inhibiting MCT1 or MCT4 impairs leukemic cell proliferation, induces two different related death-pathways and increases chemotherapeutic sensitivity of acute myeloid leukemia cells","volume":"10","author":"Saulle","year":"2020","journal-title":"Front Oncol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016400","article-title":"Elevated\u00a0lactate in AML bone marrow contributes to macrophage polarization via\u00a0GPR81 signaling","volume":"10","author":"Soto","year":"2026","journal-title":"Blood Adv"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08575-7","article-title":"Intrinsic electrical activity drives small-cell lung cancer progression","volume":"639","author":"Peinado","year":"2025","journal-title":"Nature"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2010.07.013","article-title":"Lactate dehydrogenase as prognostic factor in limited and extensive disease stage small cell lung cancer - a retrospective single institution analysis","volume":"104","author":"Hermes","year":"2010","journal-title":"Respir Med"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1016\/b978-0-12-801238-3.11402-3","article-title":"Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer","volume":"20","author":"Pola\u0144ski","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.116125","article-title":"Lactate represses MHC-I antigen presentation via H4K5 lactylation-PRC2 in small cell lung cancer subtype A","volume":"170","author":"Cai","year":"2026","journal-title":"Int Immunopharmacol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1821271\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T04:21:53Z","timestamp":1777522913000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1821271\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":174,"alternative-id":["10.3389\/fonc.2026.1821271"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1821271","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"article-number":"1821271"}}